Zenith Drugs Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Zenith

CMP

89.00

+8.65 (10.77%)

  • DRHP
₹79

Offer Price

₹ 40.68 Cr

Issue Size

₹ 1,26,400

Min Investment

1,600

Lot size

Time Line

  • 19
    Feb 2024
    Open
  • 22
    Feb 2024
    Close
  • 23
    Feb 2024
    Finalisation of Basis of Allotment
  • 26
    Feb 2024
    Initiation of Refunds
  • 26
    Feb 2024
    Transfer of Shares to Demat Account
  • 27
    Feb 2024
    Listing Date

Objects of the Offer

  • Increase by Targeting Unexplored Markets.

  • Product Diversification.

  • Formulations and Developments.

  • Partnerships and Licensing Opportunities.

  • Regulatory Compliance.

Products & Services

  • Zenith Drugs Limited is a pharmaceutical manufacturing and trading company.

Strengths

  • Experienced Promoters and Management Team.

  • Cost Efficiency.

  • Formulation & Development.

  • Regulatory Compliance.

  • Global Reach.

Risks

  • There are outstanding legal proceedings involving the Company, Promoters and Directors. Any adverse decision in such proceeding may have a material adverse effect on its business, results of operations and financial condition.

  • Any manufacturing or quality control problems may disrupt its business operations, damage the company reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, cash flows, results of operations and financial condition.

  • The company highly depends on its major raw materials and a few key suppliers who help it procure the same. the Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.

  • The company conducts its business activities on a purchase order basis and therefore, has not entered into long-term agreements with its customers except government contracts.

  • Its business activities are exposed to fluctuations in the prices of raw materials.

Company Promoters

Promoters Holding

Issue For IPO
27.49%
Pre Holding

91.58%

Post Holding

64.09%

Top Promoters Holding

Financials

All values in Cr

Mar-2022 Mar-2023 Mar-2023 3-Yr trend
Revenue 91.66 (-) 114.52 (24.90%) 29.88 (-)
Gross Profit 91.66 (-) 114.52 (24.90%) 29.88 (-)
Net Income 91.66 (-) 114.52 (24.90%) 29.88 (-)
Assets 91.66 (-) 114.52 (24.90%) 29.88 (-)
Liabilities 91.66 (-) 114.52 (24.90%) 29.88 (-)

Peers

Company Name Revenue (Cr) Net Profit (Cr) Assets (Cr) Liabilities (Cr) ROE EPS BVPS Current Ratio Debt to Assets
Zenith Drugs Ltd 114.52 5.15 43.39 26.15 29.88 128.83 431.11 1.54 0.60
Sudarshan Pharma Industries Ltd 461.33 7.04 232.48 232.48 6.96 5.48 41.96 3.02 0.34
Sigachi Industries Ltd 302.05 43.54 373.75 373.75 16.22 14.16 87.29 11.64 0.15

Book Running Managers

  • Gretex Corporate Services Ltd

Registrar & Transfer Agent

Bigshare Services Pvt Ltd

Office No 56-2,
Pinnacle Busine.Park,
Mahakali Caves Road - Mumbai - 400093
Phone : 91-22-62638200 Fax: 91-22-63638299

Company Contact Information

K # 72/5 Village Muradpura,
NA Depalpur,
Indore - 453001
Phone : +91 84355 01867 Email : info@zenithdrugs.com www.zenithdrugs.com

Offer Related Information

Initial public offer of 51,48,800* equity shares of face value of Rs. 10.00 each ("Equity Shares") of Zenith Drugs Limited (the "Company" or the "Issuer") for cash at a price of Rs. 79.00 per equity share including a share premium of Rs. 69.00 per equity share (the "Issue Price") aggregating to Rs. 40.68 crores ("The Issue"). The issue includes a reservation of 8,52,800 equity shares aggregating to Rs. 6.74 crores will be reserved for subscription by market maker to the issue (the "Market Maker... More

Take your research to the next level.
Login now to unlock Exclusive Features!

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: